http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103864699-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 2012-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103864699-B |
| titleOfInvention | There is resisting HBV virus and have the Synthesis and applications of the new class non-nucleosides S-DABOs pyrimidone derivatives of AntiHIV1 RT activity and HCV virus function concurrently |
| abstract | The present invention relates to and have resisting HBV virus and a class non-nucleosides S-DABOs class pyrimidone derivatives having AntiHIV1 RT activity and HCV virus activity concurrently, chemical structure is shown in general formula I, and in formula, the definition of each group as is described in the claims.The new compound that chemosynthesis goes out adopts non-nucleoside pyrimidone to be parent nucleus, not easily produces resistance when suppressing HBV virus and owing to avoiding the mechanism of competing mutually with body substrate, therefore has relatively little toxic side effect.Compound with stylish synthesis also has certain restraining effect to HIV and HCV virus.n general formula I, wherein, Rn 1 for H, CHn 3 , F; Rn 2 for (p-NOn 2 ) Cn 6 hn 5 cHn 2 , (p-CN) Cn 6 hn 5 cHn 2 , (p-CHn 3 cO) Cn 6 hn 5 cHn 2 , (p-CHn 3 oOC) Cn 6 hn 5 cHn 2 , (p-NOn 2 ) Cn 6 hn 5 oCHn 2 cHn 2 , (p-NOn 2 ) Cn 6 hn 5 cHn 2 cHn 2 , Cn 6 hn 5 oCHn 2 cHn 2 cHn 2 , Cn 6 hn 5 cHn 2 oCHn 2 , (p-NOn 2 ) Cn 6 hn 5 cHn 2 cHn 2 cHn 2 , (p-NHn 2 ) Cn 6 hn 5 cHn 2 cHn 2 cHn 2 , (p-NHAc) Cn 6 hn 5 cHn 2 cHn 2 , (p-NHAc) Cn 6 hn 5 cHn 2 cHn 2 cHn 2 ; Rn 3 for H, I. |
| priorityDate | 2012-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.